Incyte (INCY) Construction in Progress (2019 - 2022)
Incyte's (INCY) quarterly Construction in Progress came in at $176.2 million in Q4 2022, down 10.74% YoY from $197.4 million in Q4 2021, and down 10.74% on a QoQ basis from $197.4 million in Q4 2021.
Incyte (INCY) Construction in Progress (2019 - 2022) Analysis & Trends
Incyte (INCY) has 4 years of Construction in Progress data on file, last reported at $176.2 million in Q4 2022.
- Quarterly Construction in Progress fell 10.74% year-over-year to $176.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $176.2 million (down 10.74% YoY) and the FY2022 annual result came in at $176.2 million, down 10.74% from the prior year.
- Construction in Progress retreated to $176.2 million in Q4 2022, from $197.4 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $197.4 million in Q4 2021 to a low of $2.0 million in Q1 2019.
- A 4-year average of $75.9 million and a median of $23.1 million in 2020 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2020 — Construction in Progress jumped 1113.04% — and 2022, when it fell 10.74%.
- Tracing INCY's Construction in Progress over 4 years: stood at $13.8 million in 2019, then jumped by 1113.04% to $167.4 million in 2020, then rose by 17.92% to $197.4 million in 2021, then slipped by 10.74% to $176.2 million in 2022.
- The last three Construction in Progress figures came in at $176.2 million (Q4 2022), $197.4 million (Q4 2021), and $140.7 million (Q3 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 176.20 Mn |
| Dec 31, 2021 | 197.40 Mn |
| Sep 30, 2021 | 140.70 Mn |
| Jun 30, 2021 | 125.60 Mn |
| Mar 31, 2021 | 19.10 Mn |
| Dec 31, 2020 | 167.40 Mn |
| Sep 30, 2020 | 23.80 Mn |
| Jun 30, 2020 | 22.40 Mn |
| Mar 31, 2020 | 18.20 Mn |
| Dec 31, 2019 | 13.80 Mn |
| Jun 30, 2019 | 3.90 Mn |
| Mar 31, 2019 | 2.00 Mn |